Welcome to our dedicated page for Collegium Pharmaceutical SEC filings (Ticker: COLL), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The SEC filings page for Collegium Pharmaceutical, Inc. (Nasdaq: COLL) provides access to the company’s official regulatory submissions as a public biopharmaceutical issuer. These documents, filed with the U.S. Securities and Exchange Commission, offer detailed information on Collegium’s financial condition, risk factors, capital structure, and governance as it advances a portfolio of pain management medications and ADHD-focused neuropsychiatry products.
Investors and analysts can use this page to review periodic reports such as annual reports on Form 10-K and quarterly reports on Form 10-Q, which describe the company’s business, key products, and risk environment, and present audited or reviewed financial statements. Current reports on Form 8-K, like those cited in recent disclosures, furnish information on material events, including quarterly financial results, earnings presentations, share repurchase authorizations, and other significant corporate actions.
For those examining executive and board matters, proxy statements on Schedule 14A and related filings provide context on governance and compensation policies. Filings related to securities offerings and credit facilities can shed light on how Collegium finances its operations and business development plans, including the use of syndicated credit arrangements and other debt instruments mentioned in company press releases.
In addition, users can monitor beneficial ownership and insider activity through forms such as Form 4, which report transactions in Collegium’s common stock by directors, officers, and certain shareholders. Understanding these filings can help readers interpret how management and insiders interact with COLL shares over time.
On Stock Titan, SEC documents for Collegium are updated as they become available from EDGAR. AI-powered tools can help summarize lengthy filings, highlight key sections on product portfolios, non-GAAP metrics, and risk factors, and make it easier to navigate complex disclosures when researching COLL as an investment or analyzing its regulatory history.
Collegium Pharmaceutical, Inc. (NASDAQ: COLL) disclosed in an 8-K filed on July 1, 2025 that its Board authorized a new share repurchase program of up to $150 million of common stock, effective immediately and running through December 31, 2026.
The company intends to execute buybacks on the open market at management’s discretion, considering prevailing market conditions and share price. Funding will come exclusively from existing cash on hand; no additional debt or equity issuance is mentioned. The filing contains no earnings figures, operational updates, or changes to prior guidance.
While the authorization does not obligate the company to repurchase the full amount, the program could reduce the share count, provide support for the stock price, and signal management’s confidence in long-term prospects. Investors should note that the timing, pace, and ultimate utilization of the $150 million limit remain subject to market dynamics and internal capital allocation priorities.